Concord Biotech Ltd

Stage 2 · Advancing · week 11Setup 4.0 WatchEven +0.6

As of 16 Oct 2026, Concord Biotech is in Stage 2 — advancing, the uptrend phase, in week 11 (since 31 Jul 2026). It closed at ₹1,339, 16.5% below its 52-week high and above its 200-day average, which is rising. In Health Care, 40.0% of stocks are in Stage 2.

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. More about the company

₹1,339
-1.06% today
₹14,008 Cr · Mid cap
Market Neutral — FadingHealth Care 40.0% in Stage 2-7.4 pts / 20dPharmaceuticals 49.6%-2.5 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

4.0 Watch

Momentum

Steady

Edge

Even +0.6

Setup-score rank among Stage 2 peers: #38 of 59 in Pharmaceuticals · #46 of 70 in Health Care

Is CONCORDBIO early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-16.5%
₹1,014.8 lo₹1,603 hi
16.5% below 52W high — deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 11
1w13w26w
Week 11 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
5.3%
200 DMA: ₹1,271.8 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.30x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -3.5% vs MA50 +2.3%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-7.9%
3M
-0.3%
6M
+29.1%
YTD
+0.8%
1Y
-16.8%
Sector
Health Care
↓ Peaking
Stage 2%
40.0%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
This stock ranks #62 of 66 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
49.6%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #52 of 56 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-08-18 → 2026-10-16
S? 43w
S2 32w
S4 42w
2023-08-182026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 43w → S3 3w → S2 32w → S3 5w → S4 11w → S1 10w → S4 42w → S1 7w → S2 11w current
Total tracked: 165 weeks across 9 stage runs.
Scan Membership
Prop Scan
Latest: 2026-09-04
Breakout Watch
Latest: 2026-07-31
11 appearances in last 60 days. First seen: 2024-07-08.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-16S2
Wk 11 · Vol 0.30x
2026-10-15S2
Wk 11 · Vol 0.23x
2026-10-14S2
Wk 11 · Vol 0.39x
2026-10-13S2
Wk 11 · Vol 0.39x
2026-10-12S2
Wk 10 · Vol 0.30x
2026-10-09S2
Wk 10 · Vol 0.72x
2026-10-08S2
Wk 10 · Vol 1.03x
2026-10-07S2
Wk 10 · Vol 0.25x
2026-10-06S2
Wk 10 · Vol 0.24x
2026-10-05S2
Wk 9 · Vol 0.31x
2026-10-01S2
Wk 9 · Vol 0.84x
2026-09-30S2
Wk 9 · Vol 0.58x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹1,450.8
200 DMA
₹1,271.8
52W High
₹1,603
52W Low
₹1,014.8
5D Low
₹1,339
Resistance levels (recent highs)
20d High
₹1,584.8
60d High
₹1,587.5
120d High
₹1,587.5
250d High
₹1,587.5
Next resistance
+18.4%
to 20d High
Ask the Market AI about CONCORDBIOAsk →
P/E (TTM)
37.0
Forward 29.1
Earnings Growth (YoY)
-16.3%
Revenue +13.7%
Dividend Yield
0.94%
P/B 6.3
About this companyHealth Care· Pharmaceuticals

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.